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PSU17 SANOFI AVENTIS, SAO PAULO, Brazil
PSU18 Amgen UK & Ireland, Uxbridge, UK
PSU19 None
PSU20 Medtronic International, Tolochenaz, Switzerland
PSU21 Haute Autorite de sante, Saint-Denis La Plaine, France
PSU22 Amgen AB, Helsinki, Finland
PSU23 None
PSU24 None
PSU25 Medtronic SARL, Tolochenaz, Switzerland
PSU26 Pfizer Brasil, Rio de Janeiro, Brazil
PSU27 Pfizer Brazil, Sa˜o Paulo, Brazil
PSU28 Pfizer Brazil, Sa˜o Paulo, Brazil
PSU29 ViforPharma, Neuilly-sur-Seine, France
PSU30 Bayer Turk, Istanbul, Turkey
PSU31 Medtronic Spinal & Biologics, Memphis, TN, USA
PSU32 Medtronic Spinal and Biologics, Memphis, TN, USA
PSU33 Novartis Corporation, East Hanover, NJ, USA
PSU34 Novartis Pharma GmbH, Nuremberg, Germany
PSU35 Novartis Pharma GmbH, Nuremberg, Germany
PSU36 DePuy Mitek, Raynham, MA, USA
PSY1 None
PSY2 Roche Farma SA, Madrid, Spain
PSY3 GlaxoSmithKline, Research Triangle Park, NC, USA; Human Genome
Sciences, Rockville, MD, USA
PSY4 Celgene Corporation, Summit, NJ, USA
PSY5 Millennium Pharmaceuticals, Inc, Cambridge, MA, USA
PSY6 OM Pharma, Lisbon, Portugal
PSY7 Adelphi Real World, Bollington, UK
PSY8 Novartis, Hellas, Greece
PSY9 Pfizer Inc, Walton Oaks, London, UK
PSY10 Shire HGT, Basingstoke, UK
PSY11 Novo Nordisk Scandinavia AB, Malmö, Sweden
PSY12 Novartis, Hellas, Greece
PSY13 None
PSY14 None
PSY15 Abbott, Rungis, France
PSY16 Abbott, Rungis, France
PSY17 GSK, Marly le Roi, France
PSY18 None
PSY19 None
PSY20 Baxter International Inc, Deerfield, IL, USA
PSY21 None
PSY22 Pfizer Hellas, Athens, Greece
PSY23 BERLIN-CHEMIE, Moscow, Russia
PSY24 None
PSY25 Pfizer Brazil, Sa˜o Paulo, Brazil
PSY26 Sanofi-Aventis, Prague, Czech Republic
PSY27 Shire HGT, Basingstoke, UK
PSY28 Menarini, Barcelona, Spain
PSY29 Department of Health UK (Ref. Ref. PHGX09A), London, UK
PSY30 Janssen de Mexico, Mexico, Mexico
PSY31 Eli Lilly and Company, Indianapolis, IN, USA
PSY32 Adelphi Real World, Bollington, UK
PSY33 Shire AG, Eysins, Switzerland
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PSY35 Forest Research Institute, Jersey City, NJ, USA
PSY36 Astellas Pharma A/S, Kastrup, Denmark
PSY37 GlaxoSmithKline, Research Triangle Park, NC, USA; Human Genome
Sciences, Rockville, MD, USA
PSY38 Forest Research Institute, Jersey City, NJ, USA
PSY39 GlaxoSmithKline, Research Triangle Park, NC, USA; Human Genome
Sciences, Inc., Rockville, MD, USA
PSY40 LFB (Laboratoire francais du Fractionnement et des Biotechnologies),
Courtaboeuf, France
PSY41 Astellas Pharma Global Development, Leiderdorp, Netherlands
PSY42 Abbott Laboratories , Istanbul, Turkey
PSY43 Eli Lilly and Company, Indianapolis, IN, USA
PSY44 Genesis Pharma, Athens, TN, Greece
PSY45 European Commission (EAHC), Luxembourg, Luxembourg
PSY46 Gru¨nenthal GmbH, Aachen, Germany
PSY47 None
PSY48 Janssen, Dublin, Ireland; Roche, Dublin, Ireland; MSD, Dublin, Ireland
PSY49 Celgene Corporation, Summit, NJ, USA
PUK1 Astellas Pharma, Kastrup, Denmark
PUK2 None
PUK3 None
PUK4 Pfizer Inc., Madrid, Spain
PUK5 Baxter Espan˜a, Valencia, Spain
PUK6 BMS, Paris, France
PUK7 None
PUK8 Bristol-Meyers Squibb, Rueil-Malmaison, France
PUK9 Pfizer Inc., New York, NY, USA
PUK10 Astellas Pharma GmbH, Munich, Germany
PUK11 Astellas Pharma s.r.o, Prague, Czech Republic
PUK12 Pfizer Pharma GmbH, Berlin, Germany
PUK13 None
PUK14 Astellas Pharma US, Inc., Northbrook, IL, USA
PUK15 Genzyme, Modena, Italy
PUK16 None
PUK17 GlaxoSmithKline, Moscow, Russia
PUK18 None
PUK19 Pfizer Inc., Madrid, Spain
PUK20 GlaxoSmithKline, Marly le Roi, France
PUK21 Amgen SAS, Neuilly-sur-Seine, France
PUK22 BMS, Uxbridge, UK
PUK23 Abbott GmbH & Co.KG, Wiesbaden, Germany
PUK24 None
PUK25 Allergan, Inc., Irvine, CA, USA
QL1 Ministry of Health, Madrid, Spain; EuroQol Group, Rotterdam, Netherlands
QL2 None
QL3 None
QL4 University College London, London, UK
RE1 Pharmerit International, Rotterdam, Netherlands




RU2 F. Hoffmann-La Roche Ltd., Basel, Switzerland
RU3 None
RU4 Guidelines and Audit Implementation Network, Department of Health, Social
Services and Public Safety Northern Ireland, Belfast, UK
UT1 CTMM, Eindhoven, Netherlands
UT2 Janssen-Cilag GmbH, Neuss, Germany
UT3 Hoffman-La Roche, Vancouver, BC, Canada
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